Efferent therapy in the first-line drug treatment of metastatic colorectal cancer

The aim of this study is to analyse the efficacy of efferent therapy (hemosorption) as part of drug treatment in patients with metastatic colorectal cancer (mCRC) based on the use of standard first-line chemotherapy combined with the bevacizumab biosimilar. The study included 54 patients with histol...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Z. S. Kotova, T. Yu. Semiglazova, I. A. Baldueva, D. H. Latipova, D. O. Yurlov, V. V. Semiglazov, G. M. Teletaeva, A. V. Novik, A. I. Semenova, S. A. Protsenko
Format: Artigo
Langue:Russo
Publié: Remedium Group LLC 2018-07-01
Collection:Медицинский совет
Sujets:
metastatic colorectal cancer
hemosorption
bevacizumab biosimilar
first-line treatment
Accès en ligne:https://www.med-sovet.pro/jour/article/view/2554
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires